Savara(SVRA) Stock Price Today | Quotes & News

US Stock MarketDetailed Quotes

SVRA Savara

Watchlist

3.400
+0.140+4.29%

Close May 2 16:00 ET

3.400
0.0000.00%

Post 16:05 ET

586.95MMarket Cap-7.08P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16
Moomoo NewsMay 3 02:31 ET · Ratings
Savara (SVRA) Gets a Buy From Piper Sandler
TipRanksMay 2 06:59 ET · Ratings
Savara | 10-K/A: Annual report (Amendment)
SECApr 25 16:03 ET · Announcements
JMP Securities Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10
Moomoo NewsApr 24 00:32 ET · Ratings
Savara Announces New Employment Inducement Grant
BusinesswireApr 11 16:05 ET
Savara Shares Are Trading Higher After the Company Announced Encore Presentations for Its Phase 3 IMPALA-2 Trial.
BenzingaApr 9 16:20 ET

Comments

Teddy123

Apr 8 05:41

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcomi

$Savara (SVRA.US)$
Breakthrough Phase 3 Results: New Treatment Could Transform Rare Lung Disease Management

Jaguar8

Mar 27 06:55

⚫️Watchlist, MARCH 27,2025, Thursday. NFA -DrJag8

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...

Trytosaveabit

Mar 27 05:54

news

$Savara (SVRA.US)$ Savara (SVRA) said Wednesday it entered into a loan and security agreement of up to $200 million with Hercules Capital (HTGC).
The debt financing strengthens Savara's balance sheet following its filing of a biologics license application with the US Food and Drug Administration for Molbreevi to treat autoimmune pulmonary alveolar proteinosis, a rare lung disease, the company said.
If the FDA grants priority review, Molbreevi could be approved by the end of the year, Savara s...